Article
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
European journal of cancer (Oxford, England : 1990) - 1 Jan 2023
Lee Joanna, Ahmed Tasnia, Maurichi Andrea, Di Guardo Lorenzo, Stagno Anna M, Warburton Lydia, Taylor Amelia M, Livingstone Elisabeth, Rehman Saba, Khattak Adnan, Kahler Katharina C, Vanella Vito, Atkinson Victoria, Millward Michael, Schadendorf Dirk, Johnson Douglas B, Ascierto Paolo A, Hauschild Axel, Lo Serigne N, Long Georgina V, Menzies Alexander M, Carlino Matteo S
Abstract excerpt
BACKGROUND: BRAF mutant melanoma treated with BRAF ± MEK inhibitor (targeted therapy) has a high response rate; however, most patients progress (PD). Some patients have durable response, but it is unknown whether treatment can be discontinued in these patients. We describe the recurrence risk, progression patterns, response to subsequent treatment, and survival of patients with advanced melanoma who ceased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.